AADI Overview

Webcast Announcement: Aadi Bioscience, Inc. will host a webcast on March 19, 2025, to discuss its fourth quarter and full-year 2024 financial results along with recent corporate updates.

Company Overview: Aadi Bioscience is a precision oncology company focused on delivering advanced therapies for patients with challenging cancers.

Private Placement Announcement: Aadi Bioscience, Inc. has successfully closed a private placement led by Ally Bridge Group, raising approximately $100 million through the sale of 21,592,000 shares of common stock and pre-funded warrants.

Use of Proceeds: The funds will be utilized for upfront payments under a license agreement with WuXi Biologics and for general corporate purposes, supporting operations into 2028, including clinical data readouts for its ADC portfolio.

Insider Trading Activity: Scott M. Giacobello, CFO of $AADI, sold 2,806 shares on March 3, 2025, representing about 10.5% of his holdings, leaving him with 23,944 shares; there have been four insider sales and no purchases in the last six months.

Institutional Investor Movements: In the most recent quarter, 16 institutional investors increased their positions in $AADI stock while 44 decreased theirs, indicating mixed sentiment among larger shareholders.

Stockholder Approvals: Aadi Bioscience's stockholders approved several proposals during a Special Meeting, including the divestiture of its FYARRO business to KAKEN INVESTMENTS INC., a PIPE financing proposal for issuing shares, and an increase in the equity plan shares available.

Future Plans: The company aims to enhance its equity incentive plan and has received a non-binding advisory vote regarding executive compensation related to the divestiture, with final voting results to be reported in a Form 8-K.

Company Presentation Announcement: Aadi Bioscience, Inc. will present at the TD Cowen 45th Annual Healthcare Conference in Boston from March 3-5, 2025, with CEO Dave Lennon scheduled to speak on March 3, 2025.

Company Overview: Aadi Bioscience focuses on precision oncology, aiming to enhance therapies for patients with challenging cancers, and more information can be found on their website.

Appointment of New CSO: Aadi Bioscience has appointed Dr. David Dornan as Chief Scientific Officer, bringing over 20 years of experience in oncology and expertise in antibody-drug conjugates (ADCs) to advance the company's new ADC portfolio.

Strategic Developments: The company is implementing a strategic plan that includes selling FYARRO to Kaken Pharmaceuticals for $100 million, in-licensing a promising ADC portfolio from WuXi Biologics, and securing $100 million in private placement financing to support these initiatives.